IVF Media G5 - Procedural steps and scientific information after initial consultation

IVF Media G5 - Procedural steps and scientific information after initial consultation (archive)

Human medicines European public assessment report (EPAR): Beqvez (previously Durveqtix), fidanacogene elaparvovec, Date of authorisation: 24/07/2024, Revision: 3, Status: Withdrawn

Human medicines European public assessment report (EPAR): Roclanda, latanoprost / netarsudil, Date of authorisation: 07/01/2021, Revision: 9, Status: Authorised

Guideline on core SmPC for human normal immunoglobulin for subcutaneous and intramuscular administration (SCIg/IMIg)

Medicines during pregnancy and breastfeeding

Human medicines European public assessment report (EPAR): Tecvayli, teclistamab, Date of authorisation: 23/08/2022, Revision: 6, Status: Authorised

Draft guideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg) - Revision 2

Pharmacovigilance Risk Assessment Committee (PRAC): 7 - 10 April 2025, European Medicines Agency, Amsterdam, the Netherlands, from 7 April 2025 to 10 April 2025

Minutes of the PRAC meeting 07-10 April 2025